Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coronavirus Update: Moderna’s COVID-19 Vaccine Passes First Test In Elderly Patients

Encouraging Results From Phase I Study

Executive Summary

Plus: Korea approves Celltrion antibody trial in mild patients, promising signs for Translate Bio's mRNA candidate in animal studies.

You may also be interested in...



US COVID Vaccine Early Distribution Plans Assume Emergency Use Authorization First

CDC developing vaccine distribution plans with four states and one large city that will serve as a foundation for other jurisdictions; plans include provisions for all potential vaccines, but logistics will vary depending on product, especially given the cold chain issues associated with mRNA vaccines from Pfizer and Moderna.

Coronavirus Update: Moderna Could Have Advantage Over Pfizer’s Cold Chain

Cold chain distribution requirements are a major downside for mRNA-based vaccines, but Moderna may have the edge over Pfizer/BioNTech's candidate.

Executives On The Move: New CEOs At Advicenne, Almirall And CohBar

Executive reshuffle at Karyopharm Therapeutics, plus new chief financial officers at Redx Pharma and Vaccibody.

Topics

Related Companies

UsernamePublicRestriction

Register

SC142862

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel